Intra-cellular therapies prices public offering of common stock

New york, jan. 04, 2022 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. all of the shares in the offering will be sold by intra-cellular therapies, with gross proceeds to intra-cellular therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses. intra-cellular therapies has granted the underwriters a 30-day option to purchase up to an additional 1,428,571 shares on the same terms and conditions. the offering is expected to close on january 7, 2022, subject to the satisfaction of customary closing conditions.
ITCI Ratings Summary
ITCI Quant Ranking